Tag Archives: Leland Gershell

Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Wednesday at $2.65. According to TipRanks.com, Gershell is a 5-star analyst with

Oppenheimer Assigns a Buy Rating on Miragen Therapeutics (MGEN)

Oppenheimer analyst Leland Gershell assigned a Buy rating to Miragen Therapeutics (MGEN – Research Report) today and set a price target of $37.00. The company’s shares closed last Wednesday at $16.80. According to TipRanks.com, Gershell is a 4-star analyst with

Oppenheimer Releases a Buy Rating on Agile Therapeutics (AGRX)

Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics (AGRX – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $3.00. According to TipRanks.com, Gershell is a 3-star analyst with

Oppenheimer Gives a Buy Rating to Agile Therapeutics (AGRX)

Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics (AGRX – Research Report) today and set a price target of $12.00. The company’s shares closed last Thursday at $2.92. According to TipRanks.com, Gershell is a 2-star analyst with

Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI)

Oppenheimer analyst Leland Gershell assigned a Buy rating to CASI Pharmaceuticals (CASI – Research Report) today and set a price target of $5.00. The company’s shares closed last Monday at $1.92. According to TipRanks.com, Gershell is a 1-star analyst with

Oppenheimer Gives a Hold Rating to Alnylam Pharma (ALNY)

In a report released today, Leland Gershell from Oppenheimer assigned a Hold rating to Alnylam Pharma (ALNY – Research Report), with a price target of $156.00. The company’s shares closed last Wednesday at $146.68. According to TipRanks.com, Gershell is a